The cardiovascular specialist needs to buy its way to growth – and it has marked an interest in a handful of smaller companies.
Medtronic’s quarterly results yesterday might presage a recovery, and some groups are in dire need of one.
The deal is a late entrant into 2020's top five mergers and acquisitions.
Though orthopaedics companies have begun to recover from the second quarter’s horrors, it is clear that the third quarter belongs to the diagnostics specialists.
The new regulatory scheme poses problems – but also opportunities, in the shape of possible alignment with the US.
Welcome to the calm before the Covid-19 storm.